

# Screening for genital chlamydia infection (Protocol)

Low N, Redmond S, Uusküla A, van Bergen J, Ward H, Andersen B, Götz H



**THE COCHRANE  
COLLABORATION®**

This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2013, Issue 12

<http://www.thecochranelibrary.com>

**WILEY**

---

Screening for genital chlamydia infection (Protocol)

Copyright © 2013 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration.

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
BACKGROUND . . . . .	1
OBJECTIVES . . . . .	3
METHODS . . . . .	3
ACKNOWLEDGEMENTS . . . . .	9
REFERENCES . . . . .	10
APPENDICES . . . . .	13
CONTRIBUTIONS OF AUTHORS . . . . .	14
DECLARATIONS OF INTEREST . . . . .	15
SOURCES OF SUPPORT . . . . .	15

[Intervention Protocol]

# Screening for genital chlamydia infection

Nicola Low<sup>1</sup>, Shelagh Redmond<sup>1</sup>, Anneli Uusküla<sup>2</sup>, Jan van Bergen<sup>3</sup>, Helen Ward<sup>4</sup>, Berit Andersen<sup>5</sup>, Hannelore Götz<sup>6</sup>

<sup>1</sup>Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland. <sup>2</sup>Department of Public Health, University of Tartu, Tartu, Estonia. <sup>3</sup>Department of General Practice and Family Medicine, University of Amsterdam, Amsterdam, Netherlands. <sup>4</sup>Department of Infectious Disease Epidemiology, Imperial College London, London, UK. <sup>5</sup>Department of Public Health Programmes, Randers, Denmark. <sup>6</sup>Department of Infectious Disease Control, Rotterdam-Rijnmond Public Health Service, Rotterdam, Netherlands

Contact address: Nicola Low, Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11, Bern, CH-3012, Switzerland. [low@ispm.unibe.ch](mailto:low@ispm.unibe.ch).

**Editorial group:** Cochrane Sexually Transmitted Infections Group.

**Publication status and date:** New, published in Issue 12, 2013.

**Citation:** Low N, Redmond S, Uusküla A, van Bergen J, Ward H, Andersen B, Götz H. Screening for genital chlamydia infection. *Cochrane Database of Systematic Reviews* 2013, Issue 12. Art. No.: CD010866. DOI: 10.1002/14651858.CD010866.

Copyright © 2013 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. This is an open access article under the terms of the [Creative Commons Attribution-Non-Commercial](#) Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

## ABSTRACT

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effects and safety of chlamydia screening in pregnant and non-pregnant women and in men, compared with standard care, on chlamydia transmission and on complications of infection.

## BACKGROUND

### Description of the condition

Genital infections caused by *Chlamydia trachomatis* serovars D-K are the most prevalent bacterial sexually transmitted infection worldwide, with an estimated 106 million people being infected in 2008 (WHO 2012). In this protocol we use the term 'chlamydia' to describe these infections. Chlamydia is the most common notifiable infection in the USA, with 1,307,893 infections reported in 2011 compared with 309,341 cases of gonorrhoea, which is the second most common notifiable condition (CDC 2010). Chlamydia is also the most commonly reported infection in Europe (ECDC 2011), Australia (DoHA 2011) and Canada (PHAC 2006). Chlamydia is most common in young sexually ac-

tive adults. The prevalence of chlamydia has been estimated to be about 3% to 5% in nationally representative samples of sexually experienced women and men aged 25 years and under in high-income countries (Fenton 2001; Klavs 2004; Miller 2004; Goulet 2010; Bozicevic 2011).

*C. trachomatis* is a gram negative obligate intracellular bacterium, which infects columnar epithelium in the lower genital tract in women and can also infect the rectum, pharynx, conjunctiva (Stamm 2008) and placenta (Rours 2011). Chlamydia infection causes complications, most commonly resulting from spread from the lower to the upper genital tract. Upper genital tract infection occurs in both sexes but is more common and has more severe consequences in women (Stamm 2008). In women, chlamydia ascends to the upper genital tract in approximately 10% of cases to cause symptomatic pelvic inflamma-

tory disease (PID) (Oakeshott 2010; Herzog 2012). The resulting tubal damage can then cause ectopic pregnancy, tubal infertility and chronic pelvic pain (Paavonen 2008). Although about 45% of tubal infertility might be attributable to chlamydia infection (Price 2012), the probability of tubal infertility in women who have had chlamydia is estimated to be only 1% to 4% (Land 2010; Kavanagh 2013). Chlamydia infection in pregnancy is associated with preterm labour (Rours 2011) and can infect the neonate, causing ophthalmia neonatorum and atypical pneumonia (Kohlhoff 2008). *C. trachomatis* can cause epididymo-orchitis in men, but its role in prostatitis and male infertility is not well-established (Stamm 2008). Chlamydia can also cause Reiter's syndrome in men (Stamm 2008) and is a co-factor for HIV infection, increasing both susceptibility and infectiousness (Fleming 1999). Uncomplicated genital chlamydia infections are usually asymptomatic in both women and men (Stamm 2008) and untreated infections last more than a year on average (Althaus 2010). *C. trachomatis* can be treated with tetracyclines (usually doxycycline) or macrolide (usually azithromycin) antibiotics with short-term microbiological cure rates of 90% to 95% (Manhart 2013). Immunity after chlamydia infection is incomplete and repeated chlamydia infection is common (Batteiger 2010a). In studies of women enrolled from primary care and sexual health clinics and followed up prospectively, about 25% of women treated for chlamydia had the infection detected again in the year after treatment (Scott LaMontagne 2007; Walker 2012). There are several reasons for repeated detection of chlamydia. In one prospective study amongst young women in the USA, Batteiger et al. combined information about sexual behaviour and genotype from 183 women with more than one episode of chlamydia infection to estimate that about 66% of infections were probably acquired from a new partner, 17% were re-infections from untreated or inadequately-treated sexual partners, 14% were probable antibiotic treatment failures and 3% persisted without treatment (Batteiger 2010b). There is some evidence to suggest that immunity after natural clearance of chlamydia infection lasts longer than immunity after antibiotic treatment (Geisler 2013).

## Description of the intervention

Screening of sexually active young adults is the only way to detect most chlamydia infections because of the lack of symptoms or clinical signs in most infected people. Screening is a process of identifying apparently healthy people who may be at increased risk of a disease or condition. They can then be offered information, further tests and appropriate treatment to reduce their risk and/or any complications arising from the disease or condition (UKNSC 2013).

There are two goals of screening for genital chlamydia infection: first, to control the transmission of chlamydia and reduce the prevalence of infection in the population; and second to reduce the risk of complications, especially reproductive tract complica-

tions in women (Meyers 2007; NCSP 2010). Screening is a programme, not a test (Raffle 2007). This means that screening includes the whole system of events needed to reach the endpoint of reducing the risk of disease or complications. For chlamydia infection, screening includes offering a test to diagnose *C. trachomatis*, treating people with a positive test, partner notification to identify and treat sexual partners and repeated screening to detect and treat newly acquired infection or re-infection.

The target group for chlamydia screening is usually defined by age and sex. For example, chlamydia screening in the USA is recommended for women aged 25 years and under (CDC 2010), in Australia for women under 25 years (RACGP 2007), and in the UK for women and men aged 25 years and under (NCSP 2010). Whilst behavioural and demographic factors can be used to identify groups at higher risk of chlamydia infection (Stergachis 1993; Gotz 2005), risk factors differ between populations and selective criteria can be difficult to apply in practice.

Chlamydia screening can be offered systematically, using a population register to invite people in the target age group (van den Broek 2012). More commonly, screening is recommended as an opportunistic activity to be offered to eligible young adults attending healthcare services (RACGP 2007; CDC 2010; NCSP 2010). Repeated screening is recommended in some countries, given the frequency of repeated chlamydia and the fact that young adults may change sexual partners over time. In England, the National Chlamydia Screening Programme recommends a screening test every year or after a change of sexual partner (NCSP 2010). Visits for cervical cancer screening in young women can be used as an opportunity to offer chlamydia screening in some countries, where the target age groups and screening frequency overlap. In the UK, however, cervical cancer screening is only recommended for women over 25 years.

## How the intervention might work

The way in which chlamydia screening might work depends on the goal of screening. To reduce chlamydia prevalence and incidence, the coverage of screening has to be high enough to identify and treat prevalent cases of chlamydia and to interrupt chains of chlamydia transmission in the population. Screening also has to be frequent enough to prevent repeated infections because of the limited immunity after treatment. Mathematical models show that chlamydia screening reduces prevalence over time; in several models, screening of 30% or more of the target population each year is needed to reduce chlamydia prevalence markedly (Regan 2008; Althaus 2012).

There are two ways in which screening for chlamydia might work to prevent reproductive tract complications (Peterman 2009; Herzog 2013). First, direct prevention of PID occurs if screening detects and treats an endocervical chlamydia infection in an individual woman before the infection ascends in the genital tract to cause PID and subsequent tubal damage. The effectiveness of

screening depends on the timing of progression from lower to upper genital tract infection. If PID occurs immediately, or shortly after the initial lower genital tract infection, there is no opportunity for screening to work (Smith 2007; Herzog 2012). Randomised controlled trials (RCTs) have shown that the incidence of clinically diagnosed PID is lower in women actively invited for chlamydia screening compared to those receiving usual care (Scholes 1996; Ostergaard 2000; Oakeshott 2010; Andersen 2011). Women infected with chlamydia who are enrolled into trials have persisting prevalent infections with an unknown date of infection. The trial findings and supportive evidence from mathematical modelling studies suggest, therefore, that PID development can occur during the course of infection (Herzog 2012). Second, prevention of the transmission of chlamydia through screening and treatment has an indirect effect on the risk of PID because the risk of becoming infected with chlamydia in the first place falls.

Prevention of PID should lead to a reduction in the incidence of ectopic pregnancy and tubal infertility if tubal scarring is prevented. It is, however, very difficult to measure the impact of chlamydia screening on these outcomes because women in the age groups at highest risk of chlamydia infection are usually using contraception. In one RCT, the incidence of ectopic pregnancy and infertility after 11 years of follow-up were similar in women who had received a single invitation to be screened for chlamydia and women who received usual care (Andersen 2002).

There are also potential harms of chlamydia screening. First, a woman who has been treated for chlamydia becomes susceptible and is at risk of repeated infection and PID. It has been suggested that the risk of PID is higher with subsequent chlamydia infections (Hillis 1997), possibly because repeated exposure to *C. trachomatis* antigens can cause immune mediated tubal damage (Brunham 2005). Second, being diagnosed with a sexually transmitted infection can have a negative emotional and psychological impact on the infected person (Mills 2006; Gottlieb 2011). In one study in the USA, sexual partnerships broke down for 33% of women with a positive chlamydia test result compared with 11% of those receiving a negative result (Gottlieb 2011). Third, the experience of screening can cause anxiety. In a study in the UK, however, chlamydia screening did not increase anxiety or depression and did not reduce self-esteem (Campbell 2006).

### Why it is important to do this review

Screening for chlamydia infection is widely recommended (RACGP 2007; CDC 2010; NCSP 2010; Low 2012) and widely practised. Rates of chlamydia testing amongst young adults are high (4000 to 9000 per 100,000 population) in several high-income countries (Bender 2011). There is a strong rationale for early detection and treatment of chlamydia infection in asymptomatic young adults to reduce both transmission and complications (Low 2013). Widespread screening for asymptomatic chlamydia infection has the potential to cause harm, however, especially if the

rate of repeated infection after treatment outweighs the benefits of detecting and treating asymptomatic infections, or if receiving a diagnosis of chlamydia results in the breakdown of a relationship (O'Farrell 2013). There are few data about long-term trends in chlamydia prevalence in countries that recommend chlamydia screening. In the USA, repeated cross-sectional studies show that chlamydia prevalence fell between 1999 and 2008 in 14 to 39 year olds as a whole, but not in 15 to 25 year old women, who are the target population for screening (Datta 2012).

There is a systematic review of the effectiveness of chlamydia screening interventions in studies published up to 2007 (Low 2009). There are new RCTs showing that a one-off screening invitation could reduce the incidence of PID one year later (Scholes 1996; Ostergaard 2000). Also, we know that there are new completed trials with PID (Oakeshott 2010; Andersen 2011) and transmission (van den Broek 2012) as endpoints, and at least one ongoing trial (Hocking 2012). It is therefore important to develop a Cochrane review about this issue.

## OBJECTIVES

To assess the effects and safety of chlamydia screening in pregnant and non-pregnant women and in men, compared with standard care, on chlamydia transmission and on complications of infection.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

Randomised controlled trials, non-randomised controlled trials. If there are no RCTs addressing a primary outcome of chlamydia screening, we will include non-randomised studies. Chlamydia screening is a complex population-based intervention, one aim of which is to reduce chlamydia prevalence in a population. This is an outcome that is unlikely to be studied in RCTs (Cochrane 2011). Cluster-randomisation is technically possible, but our previous systematic review did not find any RCTs that examined the effect of chlamydia screening on chlamydia transmission (Low 2009). With cluster allocation, trials will be eligible if the groups receive the intervention during different time periods, as long as baseline and outcome data were collected prospectively using the same criteria throughout the trial period. The risk of bias in methods of allocation will be assessed and results from randomised and non-randomised study designs will be analysed separately.

We will exclude cohort studies, case-control studies, and interrupted time-series studies.

### Types of participants

Women and men (heterosexual or men who have sex with men) aged over 13 years in any setting. The minimum age group is arbitrary but aims to identify only studies of sexually transmitted chlamydia infections.

### Types of interventions

Intervention: Screening for sexually transmitted genital chlamydia infection, defined as the offer of a test to apparently healthy people to identify those at increased risk of chlamydia infection. This definition is adapted from the UK National Screening Committee (UKNSC 2013). We will include any test used to diagnose genital chlamydia infection.

Comparison: Inactive control (no offer of screening or standard care).

### Types of outcome measures

Eligible trials must include at least one of the pre-specified primary outcomes. The primary outcomes will be measures of morbidity that a chlamydia screening programme aims to prevent. One criterion for assessing the effectiveness of a screening programme is that 'There should be evidence from high quality Randomised Controlled Trials that the screening programme is effective in reducing mortality or morbidity' (<http://www.screening.nhs.uk/criteria>).

### Primary outcomes

We include one primary outcome for each goal of chlamydia screening:

- Outcome for *C. trachomatis* transmission: Prevalence of chlamydia infection in women and men at least 12 months after the start of the screening intervention. Prevalence is estimated as the number of positive chlamydia tests divided by the number of people tested.

- Outcomes for reproductive tract morbidity: Incidence of upper genital tract infection in women and men in the 12 months after the offer of screening. Pelvic inflammatory disease (women) or epididymitis (men) are clinical diagnoses, made using clinical criteria defined in advance by the authors. Examples include criteria published by the US Centers for Disease Control and Prevention (CDC 2010), or Hager and Eschenbach (Hager 1983).

- Outcome for chlamydia infection in pregnancy: Incidence of preterm delivery. Preterm delivery is defined as delivery at a gestational age of less than 37 weeks, with subgroups of gestational ages less than 32 weeks and less than 35 weeks (Rours 2011).

### Secondary outcomes

Outcomes measured in all participants:

- Proportion of participants receiving the intervention, defined as the number tested for chlamydia divided by the number eligible and invited to take part.

- Harms of screening, including psychological distress, partner violence, relationship breakdown, using definitions described by the authors.

Outcomes measured in women who were not pregnant during the trial or in men:

- Prevalence of chronic female pelvic pain, defined as patient-reported pain in the lower abdomen or pelvis lasting at least six months (Paavonen 2008).

- Prevalence of female or male infertility, defined using a clinical definition of lack of pregnancy despite unprotected intercourse for 12 months or more (Paavonen 2008).

Outcomes measured in women who were pregnant during the trial, or in their infant:

- Incidence of *C. trachomatis* neonatal conjunctivitis, defined as *C. trachomatis* isolated from the conjunctiva by culture or detected by nucleic acid amplification test (Kohlhoff 2008).

- Incidence of *C. trachomatis* neonatal pneumonitis, defined as signs of lower respiratory tract infection presenting between 4 and 12 weeks with *C. trachomatis* isolated from the nasopharynx by culture or detected by nucleic acid amplification test (Kohlhoff 2008).

The following outcome will not be included: uptake of chlamydia screening. Screening uptake is an intermediate outcome. The relationship between uptake of screening and the primary outcomes has not been quantified so, for a given level of screening uptake, it is not possible to predict the expected reduction in chlamydia prevalence or incidence of pelvic inflammatory disease.

### Search methods for identification of studies

We will attempt to identify trials meeting the inclusion criteria irrespective of their language, publication date and publication status (published, unpublished, in press, and in progress). We will use both electronic searching in bibliographic databases and hand-searching, as described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011a).

The results of all searches will be downloaded and managed using Endnote bibliographic software. Duplicate records of the same study will be deleted.

### Electronic searches

We will contact the Trials Search Coordinator (TSC) of the Sexually Transmitted Infections Cochrane Review Group in order to

implement a comprehensive search strategy which seeks to capture as many relevant trials as possible in electronic databases. For this purpose, we will use a combination of controlled vocabulary (MeSH, Emtree, DeCS, including exploded terms) and free-text terms (considering spelling variants, plurals, synonyms, acronyms and abbreviations) for “genital *Chlamydia* infection” and “screening”, with field labels, truncation, proximity operators and boolean operators. The sensitivity of the search strategies will be improved by including keywords from relevant trials detected by earlier searches. We present the search strategies in [Appendix 1](#) (Electronic search strategies).

Specifically, we will search in the following electronic databases:

- MEDLINE, Ovid platform: inception to present.
- MEDLINE In-Process & Other Non-Indexed Citations, Ovid platform: inception to present.
- MEDLINE Daily Update, Ovid platform: inception to present.
- EMBASE.com: inception to present.
- The Cochrane Central Register of Controlled Trials (CENTRAL), Ovid platform: inception to present.
- LILACS, iAHx interface: inception to present.
- CINAHL: inception to present.
- Database of Abstracts of Reviews of Effects (DARE): inception to present.
- PsycINFO: inception to present.

We will searching MEDLINE using the Cochrane highly sensitive search strategy for identifying RCTs: sensitivity and precision maximizing version (2008 revision), Ovid format ([Higgins 2011a](#)). The LILACS search strategy will be combined with the RCT filter of the iAHx interface.

These searches will be updated within 6 months before publication of the review.

### Searching other resources

We will attempt to identify additional relevant trials using the following methods:

1. Searching in the Sexually Transmitted Infections (STI) Cochrane Review Group’s Specialised Register, which includes RCTs and controlled clinical trials, from 1944 to 2012, located through:

- Electronic searching in MEDLINE, EMBASE and CENTRAL.
- Handsearching in those journals not indexed in MEDLINE or EMBASE (according to the journals’ master list of the STI Cochrane Review Group): *Anatolian Journal of Obstetrics & Gynecology*, *Current Medical Literature Gynecology & Obstetrics*, *Current Obstetrics and Gynecology Reports*, *ISRN Obstetrics and Gynecology*, *Journal of South Asian Federation of Obstetrics & Gynecology*, *Obstetrics and Gynecology International*, *Obstetrics Gynaecology and Reproductive*

*Medicine, Sexual Science: the newsletter of the Society for the Scientific Study of Sexuality and Sexualities*.

2. Searching trials registers:

- WHO International Clinical Trials Registry Platform (ICTRP) portal (<http://apps.who.int/trialsearch/>): inception to present.
- ClinicalTrials.gov (<http://clinicaltrials.gov/>): inception to present.

3. Searching Web of Science®: inception to present.

4. Searching for grey literature in System for Information on Grey Literature in Europe “OpenGrey” (<http://www.opengrey.eu/>): inception to present.

5. Contacting authors of all RCTs identified by other methods. A comprehensive list of trials included in the review along with the criteria for considering studies will be sent to the first author of each included study, asking for any additional studies published or unpublished that might be relevant.

6. Handsearching conference proceeding abstracts from the following events:

- The International Society for Sexually Transmitted Diseases Research - ISSTD ( <http://www.isstd.org/>): 2007, 2009 and 2011.
- The British Association for Sexual Health and HIV - BASHH (<http://www.bashh.org/>): 2004, 2006, 2007 and 2009.
- International Congress on Infectious Diseases - ICID ( <http://www.isid.org/>): 2010 and 2012.
- The International Union against Sexually Transmitted Infections - IUSTI (<http://www.iusti.org/>): 2011 and 2012.
- International Society for Infectious Diseases - ISID (<http://www.isid.org/>): 2011.
- International Meeting on Emerging Diseases and Surveillance - IMED (<http://www.isid.org/>): 2007, 2009 and 2011.
- Interscience Conference on Antimicrobial Agents and Chemotherapy - ICAAC (<http://www.icaac.org/>): 2011 and 2012.
- The International Federation of Gynecology and Obstetrics - FIGO (<http://www.figo2012.org/home/>): 2012.

7. Handsearching previous systematic reviews and other relevant publications on the same topic.

8. Handsearching reference lists of all relevant RCTs identified by other methods.

### Data collection and analysis

#### Selection of studies

Two review authors (NL, SR) will review titles and abstracts of articles identified by the search strategy independently, using a pilot-tested form to document potential eligibility. Disagreements

will be discussed. We will obtain the full text manuscripts of all articles agreed as being potentially eligible by both review authors, articles about which the authors still disagree after discussion, and articles with no abstract if there is insufficient information available from the title or publication type to make a decision. If the disagreement cannot be resolved by discussion, the full text of the article will be obtained.

The abstracts of articles identified through searching other resources will be assessed using the same criteria as for studies identified through electronic database searches.

Two independent review authors will examine full text articles using a pilot-tested form to assess eligibility for inclusion. Studies identified by both authors as being eligible for inclusion will be included in the review. Where there are discrepancies, the authors will discuss the article and reach a consensus decision. If there is no agreement, a third independent author will adjudicate to make a final decision about eligibility.

We will use a flow chart to document the numbers of articles assessed and included or excluded at each stage, with a summary of reasons for exclusion. The flow chart will show the total number of studies included in the review and the total number of articles pertaining to these studies. We will record briefly the characteristics of studies excluded from the review if readers might expect them to have been included.

### Data extraction and management

We will develop and pilot standardised forms to extract data about:

- Study location and setting
- Trial design and power calculation
- Ethical approval
- Inclusion and exclusion criteria
- Baseline characteristics of trial participants including sex, age, sexual orientation, pregnancy status for women, diagnostic test used to detect *C. trachomatis*
- Types of intervention: opportunistic or systematic invitation for screening; number of screening rounds, screening interval
- Types of comparison group: usual care, alternative screening method
- Types of outcome: primary, secondary
- Reporting of methodological characteristics (see next section, [Assessment of risk of bias in included studies](#) for details)

We will extract the following numerical data:

- Number of people assessed for eligibility
- Numbers randomised to intervention and comparison groups
- Numbers receiving screening in intervention and comparison groups (at each screening round if multiple rounds)
- Numbers included in analyses in intervention and comparison groups
- Numbers with outcomes in intervention and comparison groups

One author (SR) will extract data about study characteristics and a second will check these details. They will resolve discrepancies by discussion or a third independent author will adjudicate.

Two appropriately authors (from all co-authors) will extract and enter numerical data independently from each included study into Epidata using a structured form. If there are multiple publications relating to the same study, data items can be extracted from different publications. If there are discrepancies between publications about a data item, we will use the data presented in the main trial publication (the publication that includes the results for the primary outcome) or the first chronological publication reporting that data item.

Articles in languages other than English will either be translated first and then duplicate data extraction conducted as above or, if there are two review authors who understand the language of publication, they will extract the data directly.

The two files will be compared using the validation function available in Epidata. Discrepancies in data extraction or data entry will be resolved by consensus. If there is no agreement a third independent author will adjudicate to make a final decision. The agreed data will be entered into Review Manager 5 (RevMan) software. If there are insufficient details given to allow the extraction of numerical data, the study will be included and the results described.

### Assessment of risk of bias in included studies

We will assess the methods reported to have been used in the design and execution of all included trials. The assessment will determine whether there is a risk of bias that would over- or underestimate the effect of the intervention on one or more outcomes ([Higgins 2011a](#)). This assessment relies on reports of methods described by trial authors in publications and, where available, trial protocols. For any trial, the findings of the assessment can only say whether there is a risk of biased results, and cannot determine whether the results themselves are or are not biased.

For both randomised and non-randomised trials we will assess the risk of five specific sources of bias: selection bias, performance bias, detection bias, attrition bias and reporting bias; and will record any other biases related to a particular trial.

For RCTs we will use the Cochrane Collaboration's 'Risk of bias' tool and criteria in the *Cochrane Handbook* (Table 8.5.d) to assess these in the relevant domains of the reported methods and results ([Cochrane 2011](#)).

Selection bias is only the domain for which there are important differences in assessing the risk of bias in randomised and non-randomised controlled trials. For non-randomised controlled trials we will use the UK National Institute of Health and Care Excellence (NICE) 'methodology checklist' for cohort studies to assess the risk of selection bias ([NICE 2012](#)). The NICE methodology checklist format follows that of the Cochrane Collaboration tool, with criteria to assess bias in each domain and a choice of low, high or unclear risk of bias. We will use the Cochrane risk of bias tool to



assess non-randomised controlled trials for risks of performance, detection, attrition and reporting biases.

Assessors will record whether there is a low, high or unclear risk of bias in each domain of each included trial and give a justification for their decision. For each included trial there will be two independent assessors, including at least one expert in trial methodology (NL) and at least one expert in chlamydia screening (HG). They will resolve discrepancies by discussion. If they cannot agree, a third author will adjudicate.

The domains and their source are summarised here:

**(1a) Random sequence generation (possible selection bias, Cochrane 'Risk of bias' tool)**

Selection bias could occur if allocation to intervention or control groups can be predicted in advance and if participants or clusters of participants are enrolled selectively. The method used to generate the allocation sequence should be unpredictable and should balance prognostic factors, on average, across intervention and comparison groups. We will assess the method as being at:

- low risk of bias (adequate description of a truly random process, e.g. random number tables, computer generated random numbers);
- high risk of bias (explicit description of an allocation process that is not truly random, e.g. odd or even dates of birth of individuals, clusters of participants selected for implementation of the intervention with subsequent enrolment of comparison groups);
- unclear risk of bias (description that does not include enough information to decide whether sequence generation was truly random or not).

**(1b) Allocation concealment (possible selection bias, Cochrane 'Risk of bias' tool)**

Selection bias can occur if participants or clusters of participants are selectively enrolled and allocated to a particular group and if their characteristics are associated with the outcome. If the sequence has been randomly generated, selective enrolment can occur if the next assignment is known before allocation. Concealment of the allocation sequence up to the point of assignment prevents selective assignment to a particular intervention group. We will assess the methods of allocation concealment as:

- low risk of bias (adequate description of a process that prevented foreknowledge of allocation up to the point at which assignment was recorded, e.g. telephone or central randomisation);
- high risk of bias (description of a process that meant that those assigning participants or clusters of participants knew or could predict the allocation in advance);
- unclear risk of bias (insufficient details to be able to decide whether the allocation was concealed or not).

**(1c) Systematic differences between comparison groups (possible selection bias, NICE 'methodology checklist')**

In a non-randomised trial, selection bias can occur because of the

lack of a random allocation sequence and concealed allocation. If the person assigning individuals or clusters to a particular group knows about the distribution of factors associated with the outcome, they might introduce selection bias. We will assess the risk of selection bias as:

- low risk of bias ((a) the reason for participant allocation to treatment groups is not expected to affect the outcomes of the study, (b) there were attempts made within the design or analysis to balance the comparison groups for potential confounders and (c) the groups were comparable at baseline for all known major confounders and prognostic factors);
- high risk of bias (any of (a) to (c) above not fulfilled);
- unclear risk of bias (insufficient details to be able to decide whether there was a risk of systematic differences between comparison groups).

**(2) Blinding of participants and personnel (possible performance bias)**

Screening is an intervention that involves systematic differences in the delivery of a health service. Personnel who offer chlamydia screening tests might offer other sexual health information, advice or interventions, such as condoms, that could affect participants' risk of chlamydia infection or another outcome. Such information and interventions could also be considered a part of the screening programme, however. Trial participants or clusters of participants in an inactive 'usual care' control group might also be considered blinded if they do not know that they are part of a trial. For each included trial, we will describe the intervention. We will consider studies as being at low risk of bias if participants were blinded or if the lack of blinding would be unlikely to affect results for a particular outcome.

**(3) Blinding of outcome assessment (possible detection bias)**

For chlamydia screening interventions, adequate descriptions of blinding of those assessing the outcomes are important. We will group outcomes that are objectively assessed, e.g. chlamydia test results obtained from automated diagnostic systems, and those that are subjective, e.g. clinical diagnosis of pelvic inflammatory disease.

The incidence of clinically diagnosed pelvic inflammatory disease is a primary outcome of chlamydia screening interventions. The main symptom is lower abdominal pain, which is common and non-specific. Knowledge of group assignment could influence the interpretation of symptoms by both trial participants and personnel delivering the intervention in unpredictable ways. For example, healthcare providers who know whether a woman has been screened for chlamydia might be more likely to assign a diagnosis of pelvic inflammatory disease to a woman who presents with abdominal pain because of increased awareness of the complications of chlamydia infection. On the other hand, they might be reassured if the test was negative or if treatment had been given and then interpret abdominal pain with or without accompanying signs as resulting from another cause. Women who have accepted or declined screening might also modify their assessment of symp-

toms or their health-seeking behaviour. For subjective outcomes, we will assess methods as follows:

- low risk of bias (adequate description of assessment that reduced the risk of bias, e.g. uniform assessment of all trials participants by an independent assessor blinded to allocation, or assessment of diagnoses by an independent assessment panel blinded to allocation);
- high risk of bias (assessment of outcomes by personnel who knew the group assignment);
- unclear risk of bias (insufficient information to determine whether outcome assessment was blinded or not).

#### **(4) Incomplete outcome data (possible attrition bias due to the amount, nature and handling of incomplete outcome data)**

For each outcome or class of outcomes we will describe the completeness of data and exclusions from analysis in each included trial. We will state whether analyses were conducted and reported according to intention-to-treat or not. Where reported we will state numbers included in the analysis as a proportion of the totals randomised to intervention and comparison groups, reasons for attrition or exclusion, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information is reported, or can be supplied by the trial authors, we will re-include missing data in our analyses. We will use a cut-off of 20% to assign trials with missing outcome data as being at low or high risk of bias. In addition, we will assess methods as being at:

- low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);
- high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; 'as treated' analysis done with substantial departure of intervention received from that assigned at randomisation);
- unclear risk of bias (insufficient information about missing data or exclusions from analysis).

#### **(5) Selective outcome reporting (possible reporting bias)**

Where available, we will assess the trial protocol and trial registration documents as well as articles or publications resulting from a trial. We will describe the documents available for each included study and assess the methods as follows:

- low risk of bias (adequate description that all pre-specified outcomes and all expected outcomes of interest to the review have been reported);
- high risk of bias (explicit evidence that not all pre-specified outcomes have been reported, that one or more reported primary outcomes were not pre-specified, that outcomes of interest are reported incompletely and cannot be used in the review, or that there are no results for a key outcome that would have been expected to have been reported);
- unclear risk of bias (insufficient information to decide whether selective reporting bias is likely or not).

#### **(6) Other biases**

For each included trial we will describe other potential sources of bias. For example, the effects of chlamydia screening can be assessed in cluster-randomised trials. We will describe design-specific risks of bias in domains such as recruitment, baseline imbalances and appropriate statistical analysis. We will report whether these are likely to result in a low, high or unclear risk of bias.

#### **(7) Overall risk of bias**

For each primary outcome we will assess the overall level of evidence provided by the included trials using the GRADE approach, as incorporated in Review Manager 5. We will produce a 'Summary of findings' table (Higgins 2011b). The level of evidence is summarised as high, moderate, low or very low. We will give justifications for changing the level of evidence depending on findings about: study limitations; consistency of results; directness of evidence; imprecision; publication bias.

#### **Measures of treatment effect**

All pre-specified primary and secondary outcomes are dichotomous.

The treatment effect or harmful effect for each, comparing the outcome in those receiving the screening intervention with the control group, can be expressed as a relative risk (RR) with 95% confidence intervals (CI). An advantage of the RR is that it can be interpreted easily for both high and low event rates. We will also calculate the risk difference (RD, 95% CI), the actual difference in the event rate between intervention and control groups. We will use the risk difference to calculate the number needed to treat to benefit (NNTB) or number needed to treat to harm (NNTH).

For the primary outcome of chlamydia prevalence, we will report the overall effect estimate at the level of the cluster, and state whether the analysis has taken into account the correlation between individuals within a cluster. We will not combine estimates from individually and cluster-randomised trials.

#### **Unit of analysis issues**

If a trial involves more than one intervention group, we will describe all of the groups in the 'Characteristics of included studies' table. We will analyse only those relevant to the pre-specified primary and secondary outcomes; however. If necessary, we will combine results of multiple intervention or comparison groups so that only single pair wise comparisons are made.

Cluster-randomised trials of chlamydia screening interventions might measure the effect of the intervention in a geographic area or a school community. In trials of chlamydia screening, the intervention affects not only individuals who are screened and treated (direct effect), but their sexual partners and members of the same sexual network (indirect effect). The indirect effect of screening can reduce the level of repeated exposure to infection of individuals within a cluster.

### Dealing with missing data

We will report the percentage of observations with missing data in each included trial. We will use sensitivity analysis to explore the effect of including or excluding trials with high levels of missing data.

For each outcome we will attempt to analyse data according to the intention-to-treat principle, with all participants included in the group to which they were randomised and exclusion only of participants with missing outcome data.

### Assessment of heterogeneity

We will report statistical heterogeneity in results between studies using  $I^2$ ,  $\tau^2$  and  $\text{Chi}^2$  statistics obtained from analyses in Review Manager 5. We will use the  $I^2$  statistic to quantify the percentage of variability between the results that is due to heterogeneity rather than sampling error (Higgins 2002). We will take into account the fact that  $I^2$  values are affected by the number of studies, the magnitude and direction of effects in individual trials, and the strength of evidence of heterogeneity. In general, we will consider  $I^2$  values less than 40% as showing little evidence of statistical heterogeneity.

### Assessment of reporting biases

We will look for evidence of publication and other reporting biases using funnel plots that plot the effect size against precision. If there are more than 10 studies in a meta-analysis we will use statistical tests of funnel plot asymmetry for continuous (Egger 1997) or binary (Harbord 2005) endpoints.

### Data synthesis

We will use narrative syntheses to describe the results of trials where there are too few studies for meta-analysis or where we consider that meta-analysis is not clinically meaningful. We will use forest plots to display results of trials examining the same outcome.

Where appropriate, we will combine data using meta-analysis conducted in Review Manager 5. If there are trials that examine the same intervention and are assumed to measure the same underlying effect in similar populations, we will use a fixed-effect model. If there is clinical heterogeneity or statistical evidence of substantial statistical heterogeneity we will use a random-effects model to estimate the average treatment effect across trials. The results will be presented as the summary RR (95% CI) with  $I^2$  and  $\tau^2$  estimates. For meta-analyses with at least three studies combined

using a random-effects model we will also calculate a prediction interval to examine the range of effect estimates that might be expected in different settings or populations (Riley 2011). We will not combine results from randomised and non-randomised trials in the same meta-analysis, but will compare these in a sensitivity analysis.

### Subgroup analysis and investigation of heterogeneity

If there is evidence of substantial heterogeneity ( $I^2$  greater than 40%) for the primary outcome measures and if there are enough trials, we will use subgroup analyses to explore it. We will explore the following subgroups:

- Sex of the patient
- Level of sexual behaviour risk of the study population (high risk, low risk)
- Uptake of the intervention (greater or less than 50%)
- Intensity of the intervention (single offer, multiple screening rounds)

For fixed-effect models based on inverse variance meta-analysis, we will use tests of interaction to examine differences between groups. For random-effects models and fixed-effect models using methods other than inverse variance we will inspect confidence intervals for the subgroup estimates.

### Sensitivity analysis

We will conduct sensitivity analyses to investigate the influence of methodological aspects of the review that might influence the results. We pre-specify the following sensitivity analyses:

1. The treatment effect for pelvic inflammatory disease incidence in RCTs assessed as being at low versus high risk of detection bias, i.e. blinded versus non-blinded assessment.
  2. The treatment effect for each primary outcome in RCTs assessed as being at low versus high risk of selection bias.
  3. The treatment effect for chlamydia prevalence in RCTs versus non-randomised studies.
  4. The treatment effect for each primary outcome in intention-to-treat versus per protocol study populations.
- We will explore additional factors in sensitivity analysis if they arise during analysis.

## ACKNOWLEDGEMENTS

None

## REFERENCES

### Additional references

#### Althaus 2010

Althaus CL, Heijne JCM, Roellin A, Low N. Transmission dynamics of Chlamydia trachomatis affect the impact of screening programmes. *Epidemics* 2010;**2**(3):123–31.

#### Althaus 2012

Althaus CL, Turner KM, Schmid BV, Heijne JC, Kretzschmar M, Low N. Transmission of Chlamydia trachomatis through sexual partnerships: a comparison between three individual-based models and empirical data. *Journal of the Royal Society Interface* 2012;**9**:136–46.

#### Andersen 2002

Andersen B, Olesen F, Moller JK, Ostergaard L. Population-based strategies for outreach screening of urogenital Chlamydia trachomatis infections: a randomized, controlled trial. *Journal of Infectious Diseases* 2002;**185**(2):252–8.

#### Andersen 2011

Andersen B, van Valkengoed I, Sokolowski I, Moller JK, Ostergaard L, Olesen F. Impact of intensified testing for urogenital Chlamydia trachomatis infections: a randomised study with 9-year follow-up. *Sexually Transmitted Infections* 2011;**87**(2):156–61.

#### Batteiger 2010a

Batteiger BE, Xu F, Johnson RE, Rekart ML. Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. *Journal of Infectious Diseases* 2010;**201** Suppl 2:178–89.

#### Batteiger 2010b

Batteiger BE, Tu W, Ofner S, Van Der Pol B, Stothard DR, Orr DP, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. *Journal of Infectious Diseases* 2010;**201**(1):42–51.

#### Bender 2011

Bender N, Herrmann B, Andersen B, Hocking JS, van Bergen J, Morgan J, et al. Chlamydia infection, pelvic inflammatory disease, ectopic pregnancy and infertility: cross-national study. *Sexually Transmitted Infections* 2011;**87**:601–8.

#### Bozicevic 2011

Bozicevic I, Grgic I, Zidovec-Lepej S, Cakalo JI, Belak-Kovacevic S, Stulhofer A, et al. Urine-based testing for Chlamydia trachomatis among young adults in a population-based survey in Croatia: feasibility and prevalence. *BMC Public Health* 2011;**11**:230.

#### Brunham 2005

Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. *Nature Reviews Immunology* 2005;**5**(2):149–61.

#### Campbell 2006

Campbell R, Mills N, Sanford E, Graham A, Low N, Peters TJ. Does population screening for Chlamydia trachomatis raise anxiety among those tested? Findings from

a population based chlamydia screening study. *BMC Public Health* 2006;**6**:106. [DOI: 10.1186/1471-2458-6-106]

#### CDC 2010

Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. *Morbidity & Mortality Weekly Report* 2010;**59**(RR-12):44–5.

#### Cochrane 2011

Reeves BC, Deeks JJ, Higgins JPT, Wells GA, Cochrane Non-Randomised Studies Methods Group. Chapter 13: Including non-randomised studies. *Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0*. Chichester: John Wiley & Sons Ltd, 2011:13.1–34.

#### Datta 2012

Datta SD, Torrone E, Kruszon-Moran D, Berman S, Johnson R, Satterwhite CL, et al. Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999–2008. *Sexually Transmitted Diseases* 2012;**39**: 92–6.

#### DoHA 2011

Australian Government Department of Health and Ageing. National Notifiable Diseases Surveillance System. <http://www9.health.gov.au/cda/Source/CDA-index.cfm> (accessed 19 January 2011).

#### ECDC 2011

European Centre for Disease Prevention and Control. Annual epidemiological report 2011. Reporting on 2009 surveillance data and 2010 epidemic intelligence data 2011. [www.ecdc.europa.eu](http://www.ecdc.europa.eu).

#### Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**(7109):629–34.

#### Fenton 2001

Fenton KA, Korovessis C, Johnson AM, McCadden A, McManus S, Wellings K, et al. Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection. *Lancet* 2001;**358**: 1851–4.

#### Fleming 1999

Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. *Sexually Transmitted Infections* 1999;**75**(1): 3–17.

#### Geisler 2013

Geisler WM, Lensing SY, Press CG, Hook EW III. Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection. *Journal of Infectious Diseases* 2013;**10.1093/infdis/jit094**:0. [PUBMED: 23470847]

#### Gottlieb 2011

Gottlieb SL, Stoner BP, Zaidi AA, Buckel C, Tran M, Leichter JS, et al. A prospective study of the psychosocial

- impact of a positive Chlamydia trachomatis laboratory test. *Sexually Transmitted Diseases* 2011;**38**(11):1004–11.
- Gotz 2005**  
Gotz HM, Van Bergen JE, Veldhuijzen IK, Broer J, Hoebe CJ, Richardus JH. A prediction rule for selective screening of Chlamydia trachomatis infection. *Sexually Transmitted Infections* 2005;**81**(1):24–30.
- Goulet 2010**  
Goulet V, de BB, Raheison S, Prudhomme M, Semaille C, Warszawski. Prevalence of Chlamydia trachomatis: results from the first national population-based survey in France. *Sexually Transmitted Infections* 2010;**86**(4):263–70.
- Hager 1983**  
Hager D, Eschenbach D. Criteria for diagnosis and grading of salpingitis. *Obstetrics and Gynecology* 1983;**61**:113–4.
- Harbord 2005**  
Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. *Statistics in Medicine* 2006;**25**:3443–57. [DOI: 10.1002/sim.2380]
- Herzog 2012**  
Herzog SA, Althaus CL, Heijne JC, Oakeshott P, Kerry S, Hay P, et al. Timing of progression of Chlamydia trachomatis infection to pelvic inflammatory disease: a mathematical modelling study. *BMC Infectious Diseases* 2012;**12**(1):187.
- Herzog 2013**  
Herzog SA, Heijne JCM, Scott P, Althaus CL, Low N. Direct and indirect effects of screening for Chlamydia trachomatis on the prevention of pelvic inflammatory disease: a mathematical modelling study. *Epidemiology* 2013;**24**(6):854–62.
- Higgins 2002**  
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* 2002;**21**(11):1539–58.
- Higgins 2011a**  
Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions*. Version 5.1.0 [updated March 2011]. Chichester, UK: John Wiley & Sons, 2011.
- Higgins 2011b**  
Higgins JP, Altman DG, Sterne JAC, Cochrane Statistical Methods Group, Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. *Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]*. Chichester, UK: John Wiley & Sons, 2011.
- Hillis 1997**  
Hillis SD, Owens LM, Marchbanks PA, Amsterdam LF, Mac Kenzie WR. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. *American Journal of Obstetrics and Gynaecology* 1997;**176**(1 Pt 1):103–7.
- Hocking 2012**  
Hocking JS, Spark S, Guy R, Temple-Smith M, Fairley CK, Kaldor J, et al. The Australian chlamydia control effectiveness pilot (ACCEPT): first results from a randomised controlled trial of annual chlamydia screening in general practice. Oral presentation O8. Abstracts of the 4th joint BASHH-ASTDA meeting in Brighton, UK, 27–29 June 2012. *Sexually Transmitted Infections* 2012;**88** Suppl 1: A3–A4.
- Kavanagh 2013**  
Kavanagh K, Wallace LA, Robertson C, Wilson P, Scoular A. Estimation of the risk of tubal factor infertility associated with genital chlamydial infection in women: a statistical modelling study. *International Journal of Epidemiology* 2013;**42**(2):493–503.
- Klavs 2004**  
Klavs I, Rodrigues LC, Wellings K, Kese D, Hayes R. Prevalence of genital Chlamydia trachomatis infection in the general population of Slovenia: serious gaps in control. *Sexually Transmitted Infections* 2004;**80**(2):121–3.
- Kohlhoff 2008**  
Kohlhoff SA, Hammerschlag MR. Chapter 83. Gonococcal and chlamydial infections in infants and children. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, et al. editor(s). *Sexually Transmitted Diseases*. Vol. 4, New York: McGraw-Hill, 2008:1613–27.
- Land 2010**  
Land JA, Van Bergen JE, Morre SA, Postma MJ. Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. *Human Reproduction Update* 2010;**16**(2):189–204.
- Low 2009**  
Low N, Bender N, Narthey L, Shang A, Stephenson JM. Effectiveness of chlamydia screening: systematic review. *International Journal of Epidemiology* 2009;**38**(2):435–48.
- Low 2012**  
Low N, Cassell JA, Spencer B, Bender N, Martin Hilber A, van Bergen J, et al. Chlamydia control activities in Europe: cross-sectional survey. *European Journal of Public Health* 2012;**22**:556–61. [DOI: 10.1093/eurpub/ckr046]
- Low 2013**  
Low N, Geisler WM, Stephenson JM, Hook EW, III, Aral SO, Fenton KA, et al. Chlamydia control: a comparative review from the USA and UK. *The New Public Health and STD/HIV Prevention*. New York: Springer, 2013. [DOI: 10.1007/978-1-4614-4526-5\_20]
- Manhart 2013**  
Manhart LE, Gillespie CW, Lowens MS, Khosropour CM, Colombara DV, Golden MR, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. *Clinical Infectious Diseases* 2013;**56**(7):934–42.
- Meyers 2007**  
Meyers DS, Halvorson H, Luckhaupt S. Screening for chlamydial infection: an evidence update for the U.S. Preventive Services Task Force. *Annals of Internal Medicine* 2007;**147**:134–41.
- Miller 2004**  
Miller WC, Ford CA, Morris M, Handcock MS, Schmitz JL, Hobbs MM, et al. Prevalence of chlamydial and

- gonococcal infections among young adults in the United States. *JAMA* 2004;**291**(18):2229–36.
- Mills 2006**  
Mills N, Daker-White G, Graham A, Campbell R. Population screening for Chlamydia trachomatis infection in the UK: a qualitative study of the experiences of those screened. *Family Practice* 2006;**23**:550–7.
- NCSP 2010**  
National Chlamydia Screening Programme, England. Core requirements. Edition 5, update 2. [www.chlamydia-screening.nhs.uk](http://www.chlamydia-screening.nhs.uk). 5, update 2. London: Health Protection Agency, August 2010.
- NICE 2012**  
UK National Institute of Health and Care Excellence. Appendix D: Methodology checklist: cohort studies. *Process and methods guides. The guidelines manual - appendices B-1*. Vol. <http://publications.nice.org.uk/pmg6>, London: National Institute of Health and Care Excellence, November 2012:21–4.
- O'Farrell 2013**  
O'Farrell N, Weiss HA. Effect of chlamydia diagnosis on heterosexual relationships. *International Journal of STD & AIDS* 2013;**24**:722–6.
- Oakeshott 2010**  
Oakeshott P, Kerry S, Aghaizu A, Atherton H, Hay S, Taylor-Robinson D, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. *BMJ* 2010;**340**:c1642.
- Ostergaard 2000**  
Ostergaard L, Andersen B, Moller JK, Olesen F. Home sampling versus conventional swab sampling for screening of chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study. *Clinical Infectious Diseases* 2000;**31**(4):951–7.
- Paavonen 2008**  
Paavonen J, Westrom L, Eschenbach D, Holmes KK, Sparling PF, Stamm WE, et al. Chapter 56: Pelvic Inflammatory Disease. *Sexually Transmitted Diseases*. 4th Edition. New York: McGraw Hill Medical, 2008:1017–50.
- Peterman 2009**  
Peterman TA, Gottlieb SL, Berman SM. Chlamydia trachomatis screening: what are we trying to do? (Commentary). *International Journal of Epidemiology* 2009;**38**(2):449–51.
- PHAC 2006**  
Public Health Association of Canada. Canadian Guidelines on Sexually Transmitted Infections, 2006 Edition. [http://www.phac-aspc.gc.ca/std-mts/sti\\_2006/sti\\_intro2006\\_e.html](http://www.phac-aspc.gc.ca/std-mts/sti_2006/sti_intro2006_e.html) 2007.
- Price 2012**  
Price MJ, Ades AE, Welton NJ, Macleod J, Turner K, Simms I, et al. How much tubal factor infertility is caused by Chlamydia? Estimates based on serological evidence corrected for sensitivity and specificity. *Sexually Transmitted Diseases* 2012;**39**(8):608–13.
- RACGP 2007**  
Royal Australian College of General Practitioners. Guidelines for Preventive Activities in General Practice. <http://www.racgp.org.au/redbook/static/index.htm>, Melbourne, 2007:1–104.
- Raffle 2007**  
Raffle A, Gray M. Screening: Evidence and practice. *Screening: Evidence and Practice*. Oxford: Oxford University Press, 2007.
- Regan 2008**  
Regan DG, Wilson DP, Hocking JS. Coverage is the key for effective screening of Chlamydia trachomatis in Australia. *Journal of Infectious Diseases* 2008;**198**(3):349–58.
- Riley 2011**  
Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ* 2011;**342**:d549.
- Rours 2011**  
Rours GI, de Krijger RR, Ott A, Willemsse HF, de GR, Zimmermann LJ, et al. Chlamydia trachomatis and placental inflammation in early preterm delivery. *European Journal of Epidemiology* 2011;**26**(5):421–8.
- Scholes 1996**  
Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. *New England Journal of Medicine* 1996;**334**(21):1362–6.
- Scott LaMontagne 2007**  
Scott LaMontagne D, Baster K, Emmett L, Nichols T, Randall S, McLean L, et al. Incidence and reinfection rates of genital chlamydial infection among women aged 16–24 years attending general practice, family planning and genitourinary medicine clinics in England: a prospective cohort study by the Chlamydia Recall Study Advisory Group. *Sexually Transmitted Infections* 2007;**83**(4):292–303.
- Smith 2007**  
Smith KJ, Cook RL, Roberts MS. Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: influence on the cost-effectiveness of different screening intervals. *Value in Health* 2007;**10**(5):358–66.
- Stamm 2008**  
Stamm WE, Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, et al. Chlamydia trachomatis Infections of the Adult. *Sexually Transmitted Diseases*. 4th Edition. New York: McGraw Hill Medical, 2008:575–93.
- Stergachis 1993**  
Stergachis A, Scholes D, Heidrich FE, Sherer DM, Holmes KK, Stamm WE. Selective screening for Chlamydia trachomatis infection in a primary care population of women. *American Journal of Epidemiology* 1993;**138**(3):143–53.

**UKNSC 2013**

UK National Screening Committee. UK Screening Portal. Screening Information. What is a screening?. <http://www.screening.nhs.uk/screening#fileid7942> (accessed 13 June 2013).

**van den Broek 2012**

van den Broek IV, van Bergen JE, Brouwers EE, Fennema HJ, Gotz HM, Hoebe CJ, et al. Effectiveness of yearly, register based screening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation. *BMJ* 2012;**345**:e4316.

**Walker 2012**

Walker J, Tabrizi SN, Fairley CK, Chen MY, Bradshaw CS, Twin J, et al. Chlamydia trachomatis incidence and re-infection among young women: behavioural and microbiological characteristics. *PloS One* 2012;**7**(5): e37778.

**WHO 2012**

World Health Organization, Department of Reproductive Health and Research. Global incidence and prevalence of selected curable sexually transmitted infections. World Health Organization 2012:1–20. [ISBN: 978 92 4 150383 9]

\* Indicates the major publication for the study

**APPENDICES****Appendix I. Electronic search strategies****MEDLINE and CENTRAL (Ovid platform)**

- 1 exp Mass Screening/
- 2 screening\$.tw.
- 3 tested.tw.
- 4 testing.tw.
- 5 or/1-4
- 6 exp Chlamydia/
- 7 chlam?di\$.tw.
- 8 exp Chlamydia trachomatis/
- 9 exp Chlamydia Infections/
- 10 or/6-9
- 11 randomized controlled trial.pt.
- 12 controlled clinical trial.pt.
- 13 randomized.ab.
- 14 placebo.ab.
- 15 clinical trials as topic.sh.
- 16 randomly.ab.
- 17 trial.ti.
- 18 or/11-17
- 19 exp animals/ not humans.sh.
- 20 18 not 19
- 21 5 and 10 and 20

Note: the CENTRAL search strategy does not include the terms #11 to #20.

**EMBASE.com**

- #1 'mass screening'/exp
- #2 screening\*:ti,ab
- #3 'screening'/exp

#4 tested:ti,ab  
 #5 testing:ti,ab  
 #6 #1 OR #2 OR #3 OR #4 OR #5  
 #7 'Chlamydia'/exp  
 #8 chlamydi\*:ti,ab  
 #9 chlamidi\*:ti,ab  
 #10 'Chlamydia trachomatis'/exp  
 #11 'chlamydiae'/exp  
 #12 #7 OR #8 OR #9 OR #10 OR #11  
 #13 'randomized controlled trial'/exp  
 #14 'single blind procedure'/exp  
 #15 'double blind procedure'/exp  
 #16 'crossover procedure'/exp  
 #17 #13 OR #14 OR #15 OR #16  
 #18 random\*:ab,ti  
 #19 placebo\*:ab,ti  
 #20 allocat\*:ab,ti  
 #21 crossover\*:ab,ti  
 #22 'cross over':ab,ti  
 #23 trial:ti  
 #24 (doubl\* NEXT/1 blind\*):ab,ti  
 #25 #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24  
 #26 #17 OR #25  
 #27 'animal'/de  
 #28 'animal experiment'/de  
 #29 'nonhuman'/de  
 #30 #27 OR #28 OR #29  
 #31 'human'/de  
 #32 #30 AND #31  
 #33 #30 NOT #32  
 #34 #26 NOT #33  
 #35 #6 AND #12 AND #34 AND [embase]/lim

#### LILACS (iAHx interface)

(mh:(tamizaje masivo)) OR (ti:(tamizaje)) OR (ab:(tamizaje)) OR (ti:(tamización)) OR (ab:(tamización)) OR (mh:(cribado)) OR (ti:(cribado)) OR (ab:(cribado)) AND (mh:(chlamydia)) OR (ti:(chlamydi\*)) OR (ab:(chlamydi\*)) OR (ti:(chlamidi\*)) OR (ab:(chlamidi\*)) OR (ti:(clamidia\*)) OR (ab:(clamidia\*)) OR (mh:(chlamydia trachomatis)) OR (mh:(infecciones por chlamydia)) AND db:(“LILACS”) AND type\_of\_study:(“clinical\_trials”)

#### Other resources

“Screening” and “*Chlamydia*” in title, abstract and keywords.



## CONTRIBUTIONS OF AUTHORS

Nicola Low drafted the protocol.

Shelagh Redmond conducted preliminary electronic databases searches.

Helen Ward, Anneli Uuskiula, Jan van Bergen, Hannelore Götz commented on and suggested revisions to the protocol.

## DECLARATIONS OF INTEREST

Berit Andersen is co-author of a completed trial that will be considered for inclusion in the review.

Jan van Bergen, Hannelore Götz and Nicola Low were co-authors on a completed trial that will be considered for inclusion in the review (Chlamydia Screening Implementation project, The Netherlands).

Nicola Low is a co-investigator on an ongoing trial that will be considered for inclusion in the review (Australian Chlamydia Control Effectiveness Pilot. ACCEPt).

Authors of included studies will not be involved in assessing and extracting data of their own studies.

## SOURCES OF SUPPORT

### Internal sources

- No sources of support supplied

### External sources

- European Centre for Disease Prevention and Control, Sweden.

Financial support for staff to conduct review as part of a project Chlamydia Control in Europe (ECDC/2011/027).